(R)-(-)-1-Aminoindane CAS 10277-74-4 Purity >98.0% (GC) E.E >98.0%

Short Description:

Chemical Name: (R)-(-)-1-Aminoindane

CAS: 10277-74-4

Purity: >98.0% (GC)

Chiral Purity (e.e.): >98.0%

Appearance: Colorless or Yellow Liquid

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-(-)-1-Aminoindane (CAS: 10277-74-4) with high quality. We can provide COA, worldwide delivery, small and bulk quantities available. If you are interested in this product, please send detailed information includes CAS number, product name, quantity to us. Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name	(R)-(-)-1-Aminoindane
Synonyms	(R)-1-Aminoindane; (R)-(-)-1-Indanamine; (1R)-Indan-1-Amine; (R)-1-Indanylamin; (R)-2,3-Dihydro-1H-Inden-1-Amine; (1R)-2,3-Dihydro-1H-Inden-1-Amine; (R)-2,3-Dihydro-1-Indenamine
CAS Number	10277-74-4
CAT Number	RF-CC358
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C9H11N
Molecular Weight	133.19
Melting Point	15℃ (lit.)
Boiling Point	96.0~97.0℃/8 mmHg (lit.)
Density	1.038 g/mL at 25℃(lit.)
Refractive Index n20/D	1.562 (lit.)
Sensitive	Air Sensitive
Solubility	Soluble in Methanol. Not Miscible or Difficult to Mix in Water
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Colorless or Yellow Liquid
Purity / Analysis Method	>98.0% (GC)
Chiral Purity (E.E.)	>98.0%
Specific Rotation [α]20/D	-18.0° ~ -15.0° (C=1.5% in MeOH)
Total Impurities	<2.00%
Infrared Spectrum	Conforms to Structure
Proton NMR Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Chiral Compound; Pharmaceutical Intermediates

Package & Storage:

Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory Audit? Factory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

Transportation? By Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom Synthesis? Can provide custom synthesis services to best fit your research needs.

Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

Application:

(R)-(-)-1-Aminoindane (CAS: 10277-74-4) is an impurity or intermediate of Rasagiline (CAS: 136236-51-6) or Rasagiline Mesylate (CAS: 161735-79-1). Rasagiline Mesylate is a potent and selective irreversible monoamine oxidase B (MAO-B) inhibitor launched in 2005 in Israel by Teva as monotherapy in patients with early Parkinson's disease and as adjuvant treatment in moderate-toadvanced disease. Lundbeck will market the drug throughout Europe. Rasagiline is in phase II clinical trials at Teva and Eisai for the treatment of Alzheimer's type dementia.